Zenas’s autoimmune drug achieves main goal in late-stage trial
Zenas BioPharma (NASDAQ:ZBIO) reported positive late-stage clinical trial results for its experimental autoimmune therapy, hitting its primary and all key secondary targets in a study that could position the treatment as a new standard of care for a rare, debilitating inflammatory condition.
The pivotal Phase 3 study, named the INDIGO trial, evaluated the efficacy and safety of obexelimab in 194 patients diagnosed with Immunoglobulin G4-Related Disease (IgG4-RD).
The trial met its primary endpoint, demonstrating a 56% reduction in the risk of disease flares compared to a placebo.
The data were simultaneously presented at the European Alliance of Associations for Rheumatology (EULAR 2026) Congress in London and published online in the New England Journal of Medicine.
According to the trial findings, 73.2% of patients treated with a weekly subcutaneous dose of obexelimab remained entirely flare-free through 52 weeks of observation, compared with 45.4% of participants assigned to the placebo group.
The therapeutic intervention also cleared all secondary milestones with statistical significance.
Notably, patients on obexelimab required far less rescue steroid intervention, averaging 329.5 mg of cumulative glucocorticoid use compared to 929.8 mg for the control arm, thereby significantly mitigating steroid-associated toxicities.
The safety and tolerability profile of the investigational therapy was comparable to the placebo group, with no new or unexpected safety signals identified during the 1-year randomized evaluation period.
Obexelimab is engineered as a bifunctional, non-cytolytic monoclonal antibody that downregulates B-cell activity by co-engaging the CD19 and FcγRIIb receptors, allowing for immune system modulation without permanently depleting vital immune cells.
The strong late-stage performance provides critical backing for Zenas's regulatory roadmap.
The clinical results follow the company's formal submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration in May 2026.
If approved, obexelimab would offer a targeted, self-administered alternative to the high-dose corticosteroids that currently dominate the management landscape for IgG4-RD patients.